Citadel Advisors’s PAVmed PAVM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-56
Closed -$11.8K 15287
2022
Q4
$12.1K Buy
56
+7
+14% +$2.64K ﹤0.01% 13527
2022
Q3
$19K Sell
49
-1,804
-97% -$1.02M ﹤0.01% 12091
2022
Q2
$780K Buy
1,853
+77
+4% +$37.2K ﹤0.01% 7602
2022
Q1
$1.05M Sell
1,776
-1,795
-50% -$1.33M ﹤0.01% 7569
2021
Q4
$3.95M Buy
3,571
+2,996
+521% +$6.51M ﹤0.01% 4776
2021
Q3
$2.21M Buy
575
+179
+45% +$564K ﹤0.01% 6099
2021
Q2
$1.14M Buy
396
+126
+47% +$298K ﹤0.01% 8018
2021
Q1
$539K Buy
+270
New +$406K ﹤0.01% 9515
2020
Q4
Sell
-79
Closed -$63K 11364
2020
Q3
$63K Buy
+79
New +$70.3K ﹤0.01% 9515
2019
Q4
Sell
-60
Closed -$26K 9567
2019
Q3
$26K Buy
60
+13
+28% +$5.94K ﹤0.01% 8878
2019
Q2
$24K Buy
+47
New +$24.8K ﹤0.01% 8916

Other funds holding PAVM

Citadel Advisors's PAVM Position: Q1 2023 in Review

Citadel Advisors sold out of PAVmed (PAVM) in Q1 2023, closing a stake of 56 shares — an estimated $11.8K sold.

Citadel Advisors first reported a position in PAVM in Q2 2019 and held it in 11 quarters. The position peaked at $3.95M in Q4 2021. 58 funds tracked by Wall St. Rank hold PAVM as of Q1 2023.

  • Citadel Advisors reported no remaining PAVmed position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 56 PAVmed shares in Q1 2023, an estimated $11.8K.
  • Citadel Advisors first reported a position in PAVmed in Q2 2019 and held it in 11 quarters.
  • Citadel Advisors's PAVmed position peaked at $3.95M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held PAVmed as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.